恩格列净联合贝那普利对糖尿病肾病患者的治疗效果分析OA

Objective:To explore the therapeutic effect of Empagliflozin combined with Benazepril on patients with diabetic nephropathy(DN).Methods:A total of 200 patients with DN admitted to Gaoqing County Maternal and Child Health Hospital from January 2021 to December 2024 were selected as the research objects.They were divided into a control group and a study group by the random number table method,with 100 cases in each group.The control group was treated with Benazepril,while the study group was treated with Empagliflozin on the basis of the control group.Both groups were treated for 2 months.The blood glucose related indicators,renal function related indicators,symptom scores and the occurrence of complications were compared between the two groups.Results:After treatment,the fasting blood glucose,2-hour postprandial blood glucose and glycated hemoglobin in both groups were lower than those before treatment,and the study group were lower than the control group,the differences were statistically significant(P<0.05).After treatment,the 24-hour urine protein quantification,serum creatinine and blood urea nitrogen in both groups were lower than those before treatment,and the study group were lower than the control group,the differences were statistically significant(P<0.05).After treatment,the symptom scores of proteinuria,edema and hypertension in both groups decreased compared with those before treatment,and the study group were lower than the control group,the differences were statistically significant(P<0.05).The incidence of complications in the study group was 7.00%,compared with 2.00%in the control group,the difference was not statistically significant(P>0.05).Conclusion:The combined application of Empagliflozin and Benazepril can effectively reduce the glycemic-related indicators of patients with DN,improve renal function,relieve clinical symptoms,and has certain application safety.